Catalyst Pharmaceuticals Recognized as One of North America's Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™

Core Insights - Catalyst Pharmaceuticals, Inc. ranked 304 on the 2025 Deloitte Technology Fast 500, achieving a revenue growth of 249% from fiscal year 2021 to 2024 [1][2] - The company attributes its growth to its best-in-class product portfolio and strong commercial capabilities, emphasizing a commitment to sustainable growth and patient care [2][6] - The Deloitte Technology Fast 500 recognizes both public and private companies based on revenue growth percentage, highlighting the agility of private enterprises in competitive markets [3][4] Company Overview - Catalyst Pharmaceuticals is focused on developing and commercializing novel medicines for patients with rare diseases, with a strong emphasis on patient care and accessibility [6] - The company has a well-established presence in the U.S. and is continuously exploring opportunities for global expansion [6] - Catalyst was also recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies, showcasing its strong market position [6]